Nano Dimension (NNDM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
26 May, 2026Executive summary
Board is focused on executing a strategic alternatives review process to maximize shareholder value, emphasizing operational discipline and monetization of non-core assets.
Murchinson Ltd. has initiated a campaign to replace three of five directors, including two previously nominated by Murchinson, aiming for control without a premium.
Board rejects Murchinson's efforts, citing lack of a credible strategic plan and risks to shareholder value.
Strategic alternatives review is expected to conclude in the near future, with all shareholders able to vote on any proposed change-of-control transaction.
Board commits to transparency, shareholder engagement, and responsible stewardship of assets.
Voting matters and shareholder proposals
Shareholders will vote on proposed changes, including any change-of-control transaction, at an upcoming extraordinary general meeting.
Board and management are soliciting proxies and encouraging shareholders to read the definitive proxy statement and use the WHITE proxy card.
Board of directors and corporate governance
Current board includes three directors initially supported by Murchinson; Murchinson now seeks to replace two of them.
Board has invited Murchinson's founder to join, subject to a cooperation agreement, but received no response.
Director Andy Sriubas will not serve on a board controlled by Murchinson.
Board emphasizes stability and continuity during the strategic review process.
Latest events from Nano Dimension
- Proxy contest aims to declassify the board, restrict poison pills, and replace key directors.NNDM
Proxy filing18 Jun 2026 - Proposed merger with Infinite Epigenetics offers a 20% premium and pivots to AI-powered diagnostics.NNDM
Proxy filing17 Jun 2026 - $890M merger forms a Nasdaq-listed AI diagnostics leader targeting the $90–94B U.S. market.NNDM
M&A announcement16 Jun 2026 - Nano and Infinite plan a merger to create an AI-powered health diagnostics company, pending approvals.NNDM
Proxy filing15 Jun 2026 - Board supports declassification but opposes director removal and other governance changes.NNDM
Proxy filing11 Jun 2026 - Shareholders will vote on strategic direction, board structure, and director changes amid a proxy contest.NNDM
Proxy filing5 Jun 2026 - Strategic plan advances with cost cuts, asset sales, and a pivotal shareholder vote ahead.NNDM
Proxy filing5 Jun 2026 - Q1 2026 revenue surged 106% year-over-year, but net loss deepened amid restructuring and impairment.NNDM
Q1 20267 May 2026 - 2025 revenue up 77% to $102.4M, Q4 up 142%, with 2026 guidance for 30%+ growth.NNDM
Q4 202531 Mar 2026